PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2015; 36(01): 66-70
DOI: 10.4103/0971-5851.151797
CONFERENCE REVIEW

Updates from the 2014 San antonio breast cancer symposium

Shaheenah Dawood
Department of Medical Oncology, Dubai Hospital, Dubai Health Authority, UAE
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

The san antonio breast cancer syposium (SABCS 2014) was an exciting one this year. Data from the SOFT trial was presented that had potential implications on the treatment of pre menapausal women with hormone receptor positive breast cancer. In a phase II trial fulvestrant was found to significantly improve progression free and overall survival compared to anastrazole in the first line treatment of women with hormone receptor positive metastatic breast cancer. We saw a number of intersting abstracts looking at trying to refine the role of platinums and exploring the role of blocking PD-1 among women with triple receptor negative breast cancer. We also saw the results of a number of trials trying to refine standard chemotherapeutic regimens. Here we will review some fon the most interesting abstracts presented this year at SABCS 2014.

Keywords

Breast cancer - ovarian suppression - triple negative - targeted therapy


Publikationsverlauf

Artikel online veröffentlicht:
12. Juli 2021

© 2015. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 2015;16:25-35.
  • 2 S6-04. Robertson JF, Llombart-Cussac A, Feltl D, Dewar J, Jasiówka M, Hewson N, et al. Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ′FIRST′ study.
  • 3 S2-02. Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, et al. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrantvsfulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer- Part I results.
  • 4 S6-03. Adelson KB, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, et al. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial.
  • 5 Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. The SOFT Investigators and the International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015;372:436-46.
  • 6 S3-09. Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC)-put name.
  • 7 S4-05. Sikov WM, Barry WT, Hoadley KA, Pitcher BN, Singh B, Tolaney SM, et al. Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/-carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance).
  • 8 S3-01. Tutt A, Ellis P, Kilburn L, Gilett C, Pinder S, Abraham J, et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012).
  • 9 S1-09. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer.
  • 10 S6-01. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1.
  • 11 S6-02. Rimawi MF, Niravath PA, Wang T, Rexer B, Forero A, Wolff AC, et al. TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer.
  • 12 S2-07. Untch M, Jackisch C, Schneeweiß A, Conrad B, Aktas B, Denkert C, et al. A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solventbased paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69.
  • 13 S3-02. Geyer Jr CE, Samuel JA, Wilson JW, Bandos H, Elledge RM, Robidoux A, et al. NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer.